OneThree Biotech Revenue and Competitors
Estimated Revenue & Valuation
- OneThree Biotech's estimated annual revenue is currently $775k per year.
- OneThree Biotech's estimated revenue per employee is $77,500
Employee Data
- OneThree Biotech has 10 Employees.
- OneThree Biotech grew their employee count by 150% last year.
OneThree Biotech's People
Name | Title | Email/Phone |
---|---|---|
1 | Associate Director, Biomarker Data Science | Reveal Email/Phone |
OneThree Biotech Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $0.6M | 4 | 0% | N/A | N/A |
#2 | $3.7M | 24 | 41% | $44M | N/A |
#3 | $6.2M | 40 | -7% | N/A | N/A |
#4 | $42M | 271 | -1% | N/A | N/A |
#5 | $12.7M | 82 | 0% | $10M | N/A |
#6 | $2.5M | 16 | 0% | N/A | N/A |
#7 | $7.5M | 45 | 0% | $51.6M | N/A |
#8 | $0.2M | 1 | -50% | N/A | N/A |
#9 | $4.3M | 26 | -16% | $3.3M | N/A |
#10 | $3.7M | 24 | 4% | N/A | N/A |
What Is OneThree Biotech?
OneThree Biotech was born out of the largest precision medicine institute in America with the purpose of decreasing the failure rate of bringing therapeutics to market using biology driven artificial intelligence. Our technology was built in a lab setting; allowing us to engineer our methodologies around real-world results. While working with major biotech and pharma partners; we’ve validated our predictions through work in target discovery, compound and combination therapy identification, toxicity prediction, biomarker selection, and much more. Our predictions have been validated with partners such as AstraZeneca, Jubilant, and more. For example, we predicted the top indication, and mechanism of action for Oncoceutics asset ONC201 which was subsequently validated in a Phase II trial.
keywords:N/AN/A
Total Funding
10
Number of Employees
$775k
Revenue (est)
150%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.9M | 10 | -37% | N/A |
#2 | $1.3M | 10 | -17% | N/A |
#3 | $0.9M | 10 | N/A | N/A |
#4 | $0.9M | 10 | N/A | N/A |
#5 | $1.4M | 10 | N/A | N/A |